In a study assessing RCB and EFS using data from the I-SPY2 trial, patients with HER2 + cancers had higher rates of pCR, consistent with our study’s finding that the HR-/HER2 + subtype had the largest number of patients with pCR23. Here, ERBB2 is linked to cancer.